Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape

Use ofIn VitroVancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide

(2015) Ronald N. Jones et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

(2015) Romney M. Humphries et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin

(2015) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin

(2015) Rodrigo E. Mendes et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Rising Rates of Carbapenem-Resistant Enterobacteriaceae in Community Hospitals: A Mixed-Methods Review of Epidemiology and Microbiology Practices in a Network of Community Hospitals in the Southeastern United States

(2014) Joshua T. Thaden et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI Breakpoints

(2014) April M. Bobenchik et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)

(2014) Helio S. Sader et al.   JOURNAL OF INFECTION

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone

(2014) Gary Zurenko et al.   Annals of Clinical Microbiology and Antimicrobials

Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam

(2013) Michael N. Dudley et al.   CLINICAL INFECTIOUS DISEASES

Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints

(2011) J. D. Turnidge et al.   CLINICAL INFECTIOUS DISEASES

Critical Assessment of Issues Applicable to Development of Antimicrobial Susceptibility Testing Breakpoints

(2011) S. G. Jenkins et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods

(2010) C. C. Bulik et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices

(2009) James H. Jorgensen et al.   CLINICAL INFECTIOUS DISEASES

Breakpoints for intravenously used cephalosporins in Enterobacteriaceae—EUCAST and CLSI breakpoints

(2008) G. Kahlmeter   CLINICAL MICROBIOLOGY AND INFECTION